Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.
OBJECTIVE
HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described.


RESULTS
Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers.


CONCLUSIONS
These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. edward_berger@nih.gov
Edward A
EA
Berger
D001691:Biological Therapy / Q000379:methods*; D003603:Cytotoxins / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000628:therapy*; D006801:Humans
D003603:Cytotoxins
J Virol. 2008 Mar;82(6):3078-89
18184707
Science. 2010 Jul 9;329(5988):174-80
20616270
Curr Gene Ther. 2010 Apr;10(2):77-90
20222863
Curr Opin Mol Ther. 2010 Aug;12(4):403-11
20677091
Science. 2010 Aug 13;329(5993):770-3
20705840
J Immunol. 2009 Nov 1;183(9):5563-74
19843940
Cancer Treat Rev. 2008 Feb;34(1):49-60
17942233
J Infect Dis. 2000 Mar;181(3):921-6
10720513
Blood. 2000 Jul 15;96(2):467-74
10887107
Curr Opin Chem Biol. 2010 Aug;14(4):529-37
20643572
PLoS Med. 2006 Nov;3(11):e427
17090209
J Drug Target. 2007 Jan;15(1):21-36
17365271
Curr Med Chem. 2009;16(33):4361-71
19835568
N Engl J Med. 2009 Feb 12;360(7):692-8
19213682
Blood. 2000 Aug 1;96(3):785-93
10910888
J Virol. 2010 Mar;84(6):2913-22
20032180
Nat Med. 2008 Nov;14(11):1264-70
18978797
PLoS Pathog. 2010 Jun 10;6(6):e1000803
20548940
Semin Oncol. 2005 Dec;32(6):591-5
16338425
Adv Drug Deliv Rev. 2008 Sep;60(12):1407-20
18508155
Nat Biotechnol. 2008 Jul;26(7):808-16
18587387
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8889-93
1701055
AIDS. 2006 Oct 3;20(15):1911-5
16988511
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
19211796
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):457-69
17537620
Cancer Sci. 2009 Aug;100(8):1359-65
19459847
Curr Opin Immunol. 2009 Apr;21(2):224-32
19304470
J Allergy Clin Immunol. 2008 Jul;122(1):22-8
18602567
Adv Drug Deliv Rev. 2009 Sep 30;61(11):977-85
19679153
Curr Opin Immunol. 2010 Apr;22(2):251-7
20171074
Mol Ther. 2002 Jun;5(6):788-97
12027564
Nat Biotechnol. 2010 Aug;28(8):839-47
20601939
Cell. 1997 Sep 5;90(5):849-57
9298897
Retrovirology. 2005 Dec 21;2:80
16371160
J Clin Oncol. 2009 Jun 20;27(18):2983-90
19414673
Nat Rev Cancer. 2008 Jun;8(6):473-80
18469827
Expert Opin Biol Ther. 2009 Nov;9(11):1445-51
19817678
Annu Rev Med. 2007;58:221-37
17059365
Hum Gene Ther. 2010 Sep;21(9):1039-42
20626322
Blood. 2010 Nov 18;116(20):4099-102
20668228
Semin Nucl Med. 2009 Mar;39(2):146-53
19187806
Nat Med. 2008 Dec;14(12):1390-5
18997777
Cancer J. 2010 Jul-Aug;16(4):336-41
20693844
PLoS One. 2009 Dec 07;4(12):e8208
19997617
Cell. 1997 Sep 5;90(5):841-7
9298896
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11511-3
9751696
Nat Biotechnol. 2007 Dec;25(12):1444-54
18066041
J Virol. 2009 Sep;83(18):9247-57
19570871
Science. 2009 Mar 6;323(5919):1304-7
19265012